Health Care Up as Novo Nordisk Rally Resumes — Health Care Roundup
Provided by
Dow Jones
Health-care companies rose amid ongoing enthusiasm about obesity drugs.
Shares of Danish drugmaker Novo Nordisk rose by more than 3% as traders bet demand would continue to rise for the company's Ozempic drug. Eli Lilly, whose Mounjaro product is set to be a key Ozempic rival, also rose.
Physician-office landlords Healthpeak Properties and Physicians Realty Trust agreed to an all-stock merger valued at $21 billion.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
October 30, 2023 17:49 ET (21:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending